FG
EW icon

Fairman Group’s Edwards Lifesciences EW Stock Holding History

Fairman Group’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.26K Hold
36
– – ﹤0.01% 248
2026
Q1 		$2.88K Hold
36
– – ﹤0.01% 253
2025
Q4 		$3.07K Hold
36
– – ﹤0.01% 256
2025
Q3 		$2.8K Hold
36
– – ﹤0.01% 217
2025
Q2 		$2.82K Hold
36
– – ﹤0.01% 196
2025
Q1 		$2.67K Hold
36
– – ﹤0.01% 193
2024
Q4 		$2.67K Hold
36
– – ﹤0.01% 216
2024
Q3 		$2.38K Hold
36
– – ﹤0.01% 256
2024
Q2 		$3.33K Hold
36
– – ﹤0.01% 223
2024
Q1 		$3.44K Hold
36
– – ﹤0.01% 218
2023
Q4 		$2.75K Buy
+36
New +$2.5K ﹤0.01% 228

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Fairman Group's EW Position: Q2 2026 in Review

Fairman Group held its Edwards Lifesciences (EW) position steady in Q2 2026 at 36 shares worth $3.26K. The position accounts for ﹤0.01% of the portfolio, ranked #248.

Fairman Group first reported a position in EW in Q4 2023 and has held it in 11 quarters since. The position peaked at $3.44K in Q1 2024. 755 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Fairman Group held 36 shares of Edwards Lifesciences worth $3.26K as of Q2 2026.
  • Fairman Group left its Edwards Lifesciences share count unchanged in Q2 2026.
  • Edwards Lifesciences made up ﹤0.01% of Fairman Group's portfolio in Q2 2026, its #248 holding.
  • Fairman Group first reported a position in Edwards Lifesciences in Q4 2023 and has held it in 11 quarters since.
  • Fairman Group's Edwards Lifesciences position peaked at $3.44K in Q1 2024.
  • 755 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Fairman Group's 13F filing for Q2 2026, filed 4 Aug 2026.